{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"layer_decay_and_expiration_management__pharmacology_toxicology","archetype_slug":"layer_decay_and_expiration_management","domain_slug":"pharmacology_toxicology","title":"Indication-Aware Reversible Medication Lifecycle Management","opportunity_summary":"A clinician-governed lifecycle process would identify active chronic medications with absent, outdated, duplicated, or newly unfavorable justification; route them through dependency and exception checks; and support documented refresh, taper, pause, continuation, or discontinuation decisions. It preserves reconstructable history, schedules revalidation, and uses monitoring and rescue criteria rather than automatic expiration. Whether the target burden is common or the lifecycle approach improves outcomes over pharmacist-led review remains unestablished.","adopter_authorizer":"The identifiable adopter is an outpatient prescribing practice or health-system medication-management program. Treatment changes remain authorized by the patient and appropriately licensed prescriber, with pharmacists and responsible specialists informing decisions.","scores":{"meaningful_impact":{"score":4,"rationale":"If stale therapies are present, reducing unnecessary exposure could materially improve toxicity risk, regimen complexity, and accountability. The proposal also addresses serious counter-risks from withdrawal and disease destabilization, but the frequency and net magnitude of the problem are unsupported."},"stakeholder_pull":{"score":3,"rationale":"Patients, prescribers, pharmacists, and specialists have recognizable interests in justified therapy and safe deprescribing, and the candidate identifies why clinicians defer changes. No sealed evidence establishes demand, workflow willingness, budget ownership, or prevalence in an adopting population."},"incremental_advantage":{"score":3,"rationale":"The scheduled lifecycle states, indication-age review, dependency gates, reversible transitions, supersession markers, and revalidation loop plausibly improve on opportunistic reconciliation or a one-time pharmacist review. Comparative benefit, workload, and safety have not been demonstrated."},"distinctiveness_plausibility":{"score":3,"rationale":"The specific composition of ongoing lifecycle governance, reversible change, and reconstructable history is coherent, but prior art is explicitly unsearched and overlap with existing deprescribing or longitudinal medication-management approaches is unknown."},"technical_implementability":{"score":3,"rationale":"A bounded workflow can use medication records, clinician review, monitoring, and documented rescue plans without autonomous treatment decisions. Implementation is constrained by unreliable indication provenance, fragmented records, unsynchronized systems, and the need for timely physiological monitoring."},"adoption_authority_feasibility":{"score":3,"rationale":"The candidate clearly retains authority with patients and licensed prescribers and assigns advisory roles to pharmacists and specialists. Feasibility is mixed because ownership may be fragmented across prescribers and every change requires coordination, notification, follow-up, and rescue capacity."},"evidence_readiness":{"score":4,"rationale":"The proposal supplies separate problem and intervention falsifiers, a nearest-rival comparison, observable audit states, safety outcomes, and explicit halt criteria. Evidence collection is nevertheless dependent on record completeness and reliable clinical adjudication."},"safety_net_benefit":{"score":4,"rationale":"One-medication-at-a-time changes, withdrawal and dependency gates, prespecified follow-up, patient-request halts, rescue or restart plans, and preserved history provide substantial safeguards. These measures cannot guarantee reversal before nonlinear withdrawal or disease-control harm occurs."},"scalability":{"score":3,"rationale":"The lifecycle structure could be applied across medications and outpatient panels, but scaling requires indication reconstruction, clinician ownership, cross-system synchronization, patient follow-up, and drug-specific monitoring. The manual and coordination burden is unmeasured."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"A bounded shadow-mode study on one outpatient panel comparing lifecycle flagging with ordinary reconciliation or one-time pharmacist review, using blinded clinical adjudication and no medication changes.","confidence":"MODERATE","assumptions":["Existing longitudinal records are accessible for the study.","The work requires pharmacist and prescriber review, data extraction, governance, analysis, and patient-data compliance.","No new production integration or prospective treatment change is included."]},"initial_deployment_startup":{"band_2026_usd":"250K_TO_1M","scope":"Startup for one outpatient program, including workflow design, record integration, lifecycle fields, flagging logic, clinical governance, staff training, consent or notification processes, monitoring design, and evaluation setup.","confidence":"LOW","assumptions":["The existing clinical record system can be configured rather than replaced.","Automation only prioritizes cases and does not alter medication orders.","The program covers a limited panel and a defined medication subset initially.","Integration complexity and data-cleaning requirements are unknown."]},"operational_launch":{"band_2026_usd":"1M_TO_5M","scope":"Initial production launch across several outpatient clinics with pharmacist review capacity, prescriber coordination, patient follow-up, rescue coverage, safety oversight, analytics, and cross-clinic implementation support.","confidence":"LOW","assumptions":["Launch extends beyond a single pilot panel but remains within one health system.","Each proposed change receives licensed-clinician authorization and bounded monitoring.","Substantial clinical labor is required because indication and dependency review cannot be fully automated.","No major replacement of core clinical systems is required."]},"annual_recurring":{"band_2026_usd":"1M_TO_5M","scope":"Annual operation of the several-clinic program, including recurring reviews, scheduled revalidation, pharmacist and prescriber time, follow-up and rescue coordination, software support, audit, privacy controls, and outcome evaluation.","confidence":"LOW","assumptions":["Clinical review and follow-up remain labor-intensive.","Program volume, medication mix, and reassessment cadence are unspecified.","Costs are for a multi-clinic health-system program, not a national deployment.","Serious adverse events do not require extraordinary program-wide remediation."]}},"research_burden":"HIGH","earliest_credible_horizon":"3_TO_12_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"YES","reason":"The sealed candidate specifies observable cases—active drugs without current indications or reassessment dates, duplicated roles, unresolved interactions, and inherited continuation—and provides a falsifier if reconciled audits find almost none."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"An outpatient medication-management program can adopt the workflow, while the candidate explicitly assigns treatment authority to the patient and licensed prescriber with pharmacist and specialist input."},"distinct_testable_incremental_claim":{"status":"YES","reason":"The proposal explicitly contrasts ongoing lifecycle management with opportunistic reconciliation and one-time pharmacist review, and defines failure as no improvement in current justification or avoidable burden, or worse safety and patient burden."},"bounded_next_evidence_step":{"status":"YES","reason":"One outpatient panel can be examined in shadow mode using the proposed flags, a named baseline comparison, blinded adjudication, and explicit problem and intervention falsifiers without changing treatment."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"Automation is restricted to identification and prioritization; automatic or abrupt discontinuation is excluded; licensed authority, patient involvement, monitoring, halt conditions, and rescue or restart plans are specified. Any later treatment-changing study would still require appropriate clinical and research governance."},"implementation_cost_scope_and_range":{"status":"UNCERTAIN","reason":"The candidate bounds an initial outpatient setting and identifies major workflow components, but supplies no panel size, staffing ratios, integration requirements, medication subset, monitoring cadence, or coordination volume from which a reliable implementation range can be established."}},"blocking_evidence":["Audited prevalence and clinical significance of undocumented, overdue, duplicated, or unexplained active therapies in the intended population.","Accuracy of medication identity, indication provenance, dependency information, and responsible-prescriber ownership in available records.","Incremental detection and adjudicated usefulness of the lifecycle method compared with ordinary reconciliation or one-time pharmacist review.","Comparative safety and patient burden of supervised changes, including withdrawal, rebound, relapse, serious adverse events, and rescue timeliness.","Operational workload, follow-up reliability, clinician participation, and cost under a defined panel size and medication scope.","Prior-art evidence establishing whether the proposed mechanism composition is meaningfully distinct from existing deprescribing and longitudinal medication-management systems."],"next_evidence_step":"Run a bounded shadow-mode study on one outpatient panel with no medication changes: apply the proposed lifecycle review and ordinary reconciliation or one-time pharmacist review to the same records, then have blinded prescriber-pharmacist adjudicators compare current-justification completeness, actionable stale-therapy findings, false flags, and reconstruction workload. Stop or redirect if nearly all therapies already have current justification and clear ownership, record provenance is too unreliable for adjudication, or the lifecycle method yields no meaningful incremental findings over the comparator.","research_questions":["What proportion of active therapies in the intended panel lack a current indication, timely benefit-risk reassessment, or clear clinical owner after full reconciliation?","How often do lifecycle flags represent unjustified continuation rather than fragmented documentation or clinically appropriate long-duration therapy?","Does the lifecycle composition identify more adjudicated actionable cases than one-time pharmacist review without creating excessive false flags or alert burden?","Which medication classes and dependency patterns require drug-specific taper, monitoring, rescue, or exclusion rules?","Can responsible clinicians coordinate and complete follow-up within the plausible withdrawal or destabilization window?","Does supervised use improve current-justification completeness or avoidable regimen burden without worsening disease control, withdrawal, serious adverse events, or patient-reported burden?","Which elements of the proposed composition are absent from existing deprescribing and longitudinal medication-management approaches?","What staffing, integration, governance, and recurring monitoring resources are required for a defined panel and medication scope?"],"recommendation":"PRIOR_ART_RESEARCH","uncertainty_constraints":["Problem prevalence and realized harm are unsupported hypotheses in the sealed material.","World novelty and distinctiveness are unmeasured because prior art is explicitly unsearched.","Comparative effectiveness and safety versus the nearest rival have not been tested.","Documentation gaps may reflect record fragmentation rather than unjustified therapy.","Reversibility is limited because rescue cannot always restore disease control before harm occurs.","Implementation cost depends on unspecified panel size, medication mix, integration complexity, staffing, and monitoring cadence.","Stakeholder demand, budget ownership, clinician participation, and scalable follow-up capacity are unknown."],"closed_book_prior_art_boundary":"This assessment establishes only the internal coherence and testability of the proposed mechanism composition. It cannot determine whether lifecycle-state governance, indication-age tracking, reversible deprescribing, supersession markers, reconstructable medication history, scheduled revalidation, or their combination already exist, how commonly they are used, or whether they outperform established approaches."}